Alseres Pharmaceuticals, Inc.

Type: Public
On the web: http://www.alseres.com

Unlike most people, the folks at Alseres Pharmaceuticals (formerly Boston Life Sciences) want to get on your nerves. The biotechnology company is developing therapies and diagnostics related to nervous system conditions, such as spinal cord injury, Parkinson's disease, and attention deficit hyperactivity disorder (ADHD). Its lead candidate is Altropane, a molecular imaging agent for diagnosing Parkinson's disease and ADHD. Another candidate, Cethrin, aims to repair nerve damage caused by spinal cord injury; Alseres licensed Cethrin from Canadian firm BioAxone Therapeutic in 2006.

Officers:
Chairman and CEO: Peter G. Savas
President and COO: Mark J. Pykett
EVP Finance and Administration, CFO, and Secretary: Biopharmaceuticals & Biotherapeutics

Competitors:
Acorda Therapeutics
Cephalon
GE Healthcare Bio-Sciences